News

News
Novartis' groundbreaking Kymriah

Scotland says no to Yescarta, but backs Kymriah

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novar

News
Oncology R&D

Pharma companies clear the R&D decks in Q4

The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies' pipelines as they tighten their focus on the projects with the most chance of a

News
AstraZeneca (AZ)

AZ's lung drug gets fast development in EU and US

Regulators in the US and Europe have fast-tracked development of AstraZeneca’s MEDI8897, an antibody drug aimed at preventing lower respiratory tract infection caused by respiratory syncyti